[go: up one dir, main page]

WO2004089973A3 - Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production - Google Patents

Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production Download PDF

Info

Publication number
WO2004089973A3
WO2004089973A3 PCT/US2004/010353 US2004010353W WO2004089973A3 WO 2004089973 A3 WO2004089973 A3 WO 2004089973A3 US 2004010353 W US2004010353 W US 2004010353W WO 2004089973 A3 WO2004089973 A3 WO 2004089973A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
proteins
peptides
methods
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/010353
Other languages
French (fr)
Other versions
WO2004089973A2 (en
Inventor
Shabnam Tangri
Bianca Mothe
Alessandro Sette
Scott Southwood
Kristen Briggs
Robert W Chestnut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/009,953 external-priority patent/US6413517B1/en
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to CA002521273A priority Critical patent/CA2521273A1/en
Priority to US10/550,675 priority patent/US20070184519A1/en
Priority to EP04749728A priority patent/EP1608672A4/en
Publication of WO2004089973A2 publication Critical patent/WO2004089973A2/en
Anticipated expiration legal-status Critical
Publication of WO2004089973A3 publication Critical patent/WO2004089973A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention provides peptides, polypeptides, proteins and/or antibodies of reduced immunogenicity. Also provided are methods of reducing the immunogenicity of peptides, polypeptides, proteins and/or antibodies. In certain embodiments, the immunogenicity of therapeutic peptides, polypeptides, proteins, and/or antibodies such as hormones, growth factors, and cytokines is reduced.
PCT/US2004/010353 1997-01-23 2004-04-02 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production Ceased WO2004089973A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002521273A CA2521273A1 (en) 2003-04-02 2004-04-02 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US10/550,675 US20070184519A1 (en) 2003-04-02 2004-04-02 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
EP04749728A EP1608672A4 (en) 2003-04-02 2004-04-02 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3671397P 1997-01-23 1997-01-23
US3743297P 1997-02-07 1997-02-07
US09/009,953 US6413517B1 (en) 1997-01-23 1998-01-21 Identification of broadly reactive DR restricted epitopes
US10/103,395 US20020160019A1 (en) 1997-01-23 2002-03-20 Identification of broadly reactive DR restricted epitopes
US45993903P 2003-04-02 2003-04-02
US60/459,939 2003-04-02

Publications (2)

Publication Number Publication Date
WO2004089973A2 WO2004089973A2 (en) 2004-10-21
WO2004089973A3 true WO2004089973A3 (en) 2006-01-26

Family

ID=33163219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/010353 Ceased WO2004089973A2 (en) 1997-01-23 2004-04-02 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production

Country Status (1)

Country Link
WO (1) WO2004089973A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008086813A2 (en) * 2007-01-19 2008-07-24 Kobenhavns Universitet Peptides derived from proteins of the insulin super-family
WO2010025321A2 (en) * 2008-08-28 2010-03-04 Facet Biotech Corporation Method for treating multiple sclerosis patients with anti-il2r antibodies
JP5792630B2 (en) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド PAN-DR binding polypeptides and uses thereof
US11524986B2 (en) * 2018-07-11 2022-12-13 Ohio University Peptide-based inhibitors of growth hormone action and methods of use thereof
CN110240644B (en) * 2019-06-28 2021-03-16 深圳市亚辉龙生物科技股份有限公司 Human growth hormone receptor mutant, human growth hormone immunogen, polyclonal antibody and detection kit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985607A (en) * 1994-12-19 1999-11-16 Cangene Corporation Recombinant DNA molecules and expression vectors for tissue plasminogen activator
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US6251939B1 (en) * 1995-06-07 2001-06-26 Promega Biosciences, Inc. Carbamate-based cationic lipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5985607A (en) * 1994-12-19 1999-11-16 Cangene Corporation Recombinant DNA molecules and expression vectors for tissue plasminogen activator
US6251939B1 (en) * 1995-06-07 2001-06-26 Promega Biosciences, Inc. Carbamate-based cationic lipids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1608672A4 *

Also Published As

Publication number Publication date
WO2004089973A2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
EP0962467A4 (en) ANTIBODIES AGAINST HUMAN PARATHORMON RELATED PEPTIDES
AU1750297A (en) Humanized green fluorescent protein genes and methods
AU6020598A (en) Dna sequences, vectors, and fusion polypeptides for secretion of polypeptides infilamentous fungi
AU5209399A (en) Recombinant constructs and systems for secretion of proteins via type iii secretion systems
DE69534778D1 (en) Cathepsin-02-protease
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
AU5671594A (en) Human tissue factor related dna segments, polypeptides and antibodies
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2455295A (en) Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
AU3199595A (en) Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
AU3321595A (en) Recombinant production of biologically active peptides and proteins
AU1952497A (en) Novel antibody-cytokine fusion protein, and methods of making and using the same
AU9574198A (en) Method of affinity cross-linking biologically active, immunogenic peptides to antibodies
AU2978697A (en) Novel peptide, process for the production of the same, and use of the same
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
EP0911397A4 (en) Tumor antigen proteins, genes thereof, and tumor antigen peptides
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
AU3866197A (en) Novel DNA and process for preparing protein using the DNA
AU2002344219A1 (en) Fusion proteins of biologically active peptides and antibodies
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU5021796A (en) Recombinant human anti-lewis b antibodies
AU2002311620A1 (en) Methods of making and using expression constructs for the expression of recombinant proteins
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2521273

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004749728

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004749728

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10550675

Country of ref document: US

Ref document number: 2007184519

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10550675

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004749728

Country of ref document: EP